Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Target Price at $31.14

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has earned a consensus rating of “Buy” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have issued a report on the stock in the last year is $31.14.

CPRX has been the subject of several recent analyst reports. Stephens started coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective for the company. Truist Financial lifted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th.

Catalyst Pharmaceuticals Stock Down 1.3 %

Shares of NASDAQ:CPRX opened at $21.74 on Friday. Catalyst Pharmaceuticals has a 52-week low of $13.00 and a 52-week high of $24.27. The stock has a market cap of $2.59 billion, a P/E ratio of 18.42, a PEG ratio of 3.36 and a beta of 0.75. The business has a fifty day moving average of $21.48 and a two-hundred day moving average of $19.02.

Insider Buying and Selling

In other news, Director Molly Harper sold 17,500 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Gary Ingenito sold 12,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the transaction, the insider now owns 51,391 shares of the company’s stock, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its stake in shares of Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 681 shares in the last quarter. nVerses Capital LLC acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at about $50,000. Larson Financial Group LLC boosted its stake in shares of Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 2,994 shares during the period. CWM LLC grew its position in shares of Catalyst Pharmaceuticals by 686.5% during the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 3,549 shares in the last quarter. Finally, Meeder Asset Management Inc. purchased a new stake in shares of Catalyst Pharmaceuticals during the second quarter worth approximately $70,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.